Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes List AFCancer Control 2006[Dec]; 13 Suppl (ä): 12-6Lenalidomide has emerged as an effective therapeutic alternative for the management of anemia in lower-risk myelodysplastic syndromes (MDS). Compelling results from phase I and phase II clinical studies prompted the US Food and Drug Administration to approve lenalidomide for the treatment of transfusion-dependent MDS patients with interstitial deletion of chromosome 5q [del(5q)]. Subsequently, the National Comprehensive Cancer Network (NCCN) has incorporated lenalidomide into their current treatment algorithm for the treatment of lower-risk del(5q) patients. This discussion examines the current NCCN guidelines for the treatment of these patients, including the management of anemia in lower-risk MDS, and discusses the potential future therapeutic applications of lenalidomide in this disease.|Algorithms[MESH]|Anemia/*drug therapy/genetics[MESH]|Antineoplastic Agents/*administration & dosage/therapeutic use[MESH]|Blood Transfusion[MESH]|Chromosome Deletion[MESH]|Chromosomes, Human, Pair 5[MESH]|Drug Delivery Systems[MESH]|Humans[MESH]|Lenalidomide[MESH]|Medical Oncology/standards/trends[MESH]|Myelodysplastic Syndromes/*drug therapy/genetics[MESH]|Practice Guidelines as Topic[MESH]|Risk Factors[MESH]|Thalidomide/administration & dosage/*analogs & derivatives/therapeutic use[MESH] |
